Hair accessories company Durham Brands has transformed its warehouse operations thanks to a partnership with supply chain technology firm Infios. Together, the companies oversaw a systems overhaul that has helped the fast-growing consumer packaged goods (CPG) firm scale rapidly, improve...
Drive near any major city and close to half the billboards along the major arteries promote personal injury attorneys. It is human nature that when something bad happens, we have to find someone to blame. Lawsuits are big business, and the lawyers are there to make sure someone pays.Of course,...
Cybersecurity researchers have disclosed details of a vulnerability in OpenAI ChatGPT that leverages the artificial intelligence (AI) assistant’s implicit trust in Markdown links and images to trigger prompt injections and open the door to phishing attacks. The technique has been codenamed...
Palo Alto Networks has warned that a recently disclosed medium-severity security flaw impacting PAN-OS and Prisma Access has come under active exploitation in the wild. The vulnerability, tracked as CVE-2026-0257 (CVSS score: 7.8), refers to a case of authentication bypass that could be...
Dutch authorities have announced the takedown of a botnet that enslaved millions of infected devices, including computers, tablets, smartphones, and IoT devices, to carry out malicious attacks. The bot network, per the Dutch Politie and the National Cyber Security Center (NCSC), consisted of at...
A novel organ-on-a-chip device that replicates the hallmarks of inflammatory bowel disease (IBD) sheds fresh light on factors underpinning disease severity and colorectal cancer risk, including the role of stromal cells and pregnancy-related hormones. Created by a multi-disciplinary research...
Fraudsters stopped storming the gates and started forging credentials to walk through the front door. Yet, many defenders are still manning the walls.
Continue reading →
Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.
Continue reading →
Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.
Continue reading →